Table 2.
Description of the FeNO (ppb) according to the asthmatic status and exposure per cohort
| |
LISA |
PIAMA |
INMA |
|---|---|---|---|
| |
n = 182 |
n = 244 |
n = 355 |
| GM (Gsd) | GM (Gsd) | GM (Gsd) | |
|
Asthma |
|
|
|
| No |
13.7 (1.9) |
10.4 (1.9) |
11.3 (2.1) |
| Yes |
30.3 (2.3) |
13.4 (2.0) |
27.3 (3.0) |
|
Endotoxin concentrations (EU/mg) |
|
|
|
| Q1 (<3.54 EU/mg) |
12.6 (1.4) |
7.8 (1.5) |
12.3 (2.4) |
| Q2 (>3.54-12.4 EU/mg) |
17.2 (1.9) |
11.5 (2.2) |
13.0 (2.2) |
| Q3 (>12.4-30.6 EU/mg) |
14.3 (2.0) |
10.1 (1.9) |
11.8 (2.1) |
| Q4 (>30.6 EU/mg) |
14.4 (2.0) |
9.7 (1.8) |
11.5 (2.2) |
|
EPS concentrations (U/mg) |
|
|
|
| <LOD |
14.2 (2.3) |
9.5 (2.0) |
10.4 (1.8) |
| T1 (<42 U/mg) |
15.2 (2.0) |
10.6 (2.0) |
11.8 (2.3) |
| T2 (>42-101 U/mg) |
13.8 (1.9) |
9.9 (1.9) |
12.1 (2.1) |
| T3 (>101 U/mg) |
16.2 (2.2) |
12.5 (1.8) |
13.2 (2.4) |
|
Glucan concentrations (ug/mg) |
|
|
|
| <LOD |
- |
9.4 (2.1) |
- |
| T1 (<1.55 μg/mg) |
15.8 (2.0) |
10.9 (1.9) |
- |
| T2 (>1.55-2.35 μg/mg) |
13.6 (1.9) |
10.3 (1.9) |
- |
| T3 (>2.35 μg/mg) |
15.4 (2.1) |
10.7 (1.8) |
- |
|
Dampness at home |
|
|
|
| Never |
14.9 (2.0) |
10.7 (1.9) |
12.9 (2.3) |
| Ever during the first 2 years of life |
14.3 (2.1) |
10.0 (2.0) |
12.1 (2.3) |
|
Cat ownership |
|
|
|
| Never |
15.5 (2.0) |
10.6 (1.9) |
12.7 (2.3) |
| Ever during the first 2 years of life |
16.1 (2.1) |
9.7 (1.8) |
10.8 (2.2) |
| Ever after the first 2 years of life |
11.4 (1.7) |
9.9 (2.4) |
15.1 (2.5) |
|
Dog ownership |
|
|
|
| Never |
15.1 (2.0) |
10.5 (2.0) |
13.3 (2.4) |
| Ever during the first 2 years of life |
13.4 (1.6) |
9.0 (1.8) |
11.6 (2.3) |
| Ever after the first 2 years of life | 15.5 (1.6) | 10.9 (2.1) | 12.3 (2.1) |
GM: geometric mean; Gsd: geometric standard deviation; Q: quartile; T: tertile; EPS: extracellular polysaccharides; <LOD: below the limit of detection.